Prof. Asita de Silva, Senior Professor of Pharmacology and Director of the Clinical Trials Unit at the University of Kelaniya, founded RemediumOne in 2009 to efficiently carry out clinical and epidemiological research programs in Sri Lanka. Prof. de Silva, an internationally recognized expert in clinical pharmacology and a pioneer in clinical trials in South Asia, has played a pivotal role in advancing clinical research infrastructure in Sri Lanka. His work spans across a broad range of areas, including drug development, vaccine trials, and public health interventions.

As we celebrate our 15th anniversary, we take this opportunity to congratulate Prof. Asita de Silva on his recent achievement of being ranked among the top 2% of scientific researchers globally by Stanford/Elsevier in 2024. This prestigious recognition, which he has received for the third consecutive year, reflects his outstanding contributions to medical research and his global impact on science.

Prof. de Silva has authored numerous high-impact publications in leading international journals, with his research focusing on hypertension, cardiovascular disease, and innovative treatments for infectious diseases like dengue. He has also been instrumental in guiding national health policies, working closely with global organizations such as the World Health Organization (WHO) and various academic institutions worldwide.

We are privileged to work with Prof. de Silva, benefiting from his vast expertise and leadership in conducting high-quality and meaningful scientific research. His commitment to mentoring the next generation of researchers continues to inspire us.

Clinical trials are regarded as the gold standard of scientific research, generating the highest level of scientific evidence. Modern medicine has evolved primarily through clinical evidence, and we are proud to be part of this important journey under his guidance.